Intu Diagnostics, a Liepzig-based startup developing a platform for completely lab-free molecular diagnostics, has closed a €1.1 million strategic bridge round- bringing their total funding secured to over €3 million.
The round was supported by BSV Ventures, SAB (Saxonian Development Bank) and business angels. The proceeds will be used to further strengthen Intu Diagnostics’ intellectual property position, conduct pilot manufacturing trials and prepare the company for scale-up ahead of its planned Seed round.
“The clinical laboratory is expanding. It no longer requires a physical facility, a power grid, or a centralised destination. At INTU Diagnostics, we are introducing the concept of ‘LAB-TO-GO’ – bringing a doctor’s office level of reliability straight to the patient’s door with a pocket-sized, power-free platform,” said the company in a public statement.
Intu Diagnostics’ strategic bridge round sits within a 2026 sample of diagnostics, molecular pathology, biosensing and adjacent HealthTech funding totalling approximately €84 million, or around €85.1 million including Intu’s new bridge round.
The closest direct comparables include ShanX Medtech’s €24 million financing for in-vitro antimicrobial susceptibility testing, Xyall’s €7.6 million raise for molecular pathology automation, Moonlight AI’s €2.8 million Seed round for AI-enabled clinical diagnostics, and Xsensio’s €6 million Series A for continuous biochemical monitoring.
In Germany, Würzburg-based NanoStruct raised €2.6 million for rapid bacterial detection, making it the clearest same-country adjacent example in 2026.
Founded in 2023, Intu Diagnostics is a diagnostics spin-off from Fraunhofer Society building a decentralised molecular diagnostics platform designed to make high-quality infectious disease testing accessible beyond centralised laboratory environments.
The company’s technology is being developed to enable testing closer to the patient including at home, in clinics and in resource-limited settings without the need for laboratory infrastructure, specialised equipment or electricity-dependent workflows.
The company’s first application focuses on HPV testing in women’s health, addressing an area where accessible, reliable and early testing can have a significant impact. Beyond HPV, Intu Diagnostics’ platform is designed to be adaptable across multiple infectious diseases, creating the potential for a broader decentralised testing infrastructure.
At the core of Intu Diagnostics’ proposition is the combination of molecular-level diagnostic quality, full lab independence and platform versatility.
By enabling completely lab-free molecular diagnostics, Intu Diagnostics aims to simplify infectious disease testing while supporting use cases where conventional laboratory-based workflows may be too slow, costly or difficult to access.
The bridge round enables Intu Diagnostics to advance key technical and commercial milestones, including IP protection, pilot manufacturing, validation activities and preparation for future scale-up.
These milestones are expected to support the company’s transition toward its upcoming Seed financing round.
